drugset / Trial / NCT00920296

DDI Study of Etravirine and GSK1265744

NCT00920296

Phase 1 Completed 12 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelBasic science

Summary

The primary objective of this study is to compare steady-state plasma PK, safety and tolerability of GSK1265744 with and without etravirine

Timeline

Start
2009-07
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabotegravir Small molecule